Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Norwich Eaton Pharmaceuticals was a prominent American pharmaceutical company based in Norwich, New York, with a history dating back to the founding of the Norwich Pharmacal Company in 1887. The company was well-regarded for its expertise in developing specialty small molecule therapeutics, particularly in the fields of anti-infectives, urology, and musculoskeletal health. Key products in its commercial portfolio included Macrodantin for urinary tract infections and Dantrium, a critical treatment for malignant hyperthermia. In 1982, the company was acquired by Procter & Gamble for approximately $371 million, serving as the cornerstone for P&G's expansion into the ethical pharmaceutical market. Its legacy assets eventually transitioned through various owners, including Warner Chilcott and later Actavis and Teva.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Norwich Eaton Pharmaceuticals.